Berenberg Sees 25% Upside in Eli Lilly as Obesity Drugs Keep Winning
Berenberg upgraded Eli Lilly from Hold to Buy and lifted its target to $1,400, citing obesity-drug leadership and a likely 2026 guidance beat.
/ 111 items
#LLY↓
Morgan Stanley Cuts Novo Nordisk to Underweight Over Growth Slowdown and Semaglutide Patent Cliff
Semaglutide still drives most of Novo Nordisk’s sales. Morgan Stanley and other banks warn the mid-2030s patent cliff and Eli Lilly competition look underpriced.
Positive Readouts, High Bar: Why the Market Faded GPCR
Phase 3 is years away, GI side effects appeared at active amylin doses, and the oral GLP-1 bar is already high.
Lilly Acquires Merida to Advance Treatments for Autoimmune and Allergic Diseases
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion. Merida aims to remove disease-causing antibodies in Graves’ disease, TED and allergies.
Biotech Firm OmniAb Rises Sharply After Signing Global Deal with Eli Lilly
OmniAb signs a global license deal with Eli Lilly focused on ion channel drug discovery, with an upfront payment, milestones, and tiered royalties.
Berenberg Downgrades Novo Nordisk to Hold as ‘Battle of the Pills’ Heats Up
Novo Nordisk faces tougher H2. Berenberg downgrades to Hold on rising rivalry with Lilly’s Foundayo.